Browse by author
Lookup NU author(s): Dr R Neely
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© The Author(s) 2020. Lipoprotein(a) has long been regarded as a risk factor for cardiovascular disease; however, its routine use in clinical practice has been hampered by difficulties inherent in the measurement of this complex lipoprotein. The major challenges relate to its size heterogeneity and related issues including (1) use of appropriate calibrators (2) standardization of calibration protocols (3) traceability and (4) reporting units. In the UK, results from the current EQA schemes for lipoprotein(a) suggest that there is considerable work required to standardize lipoprotein(a) measurement. This is becoming increasingly pertinent with the increasing recognition of lipoprotein(a) as an independent risk factor for cardiovascular disease in international guidelines and the emergence of novel antisense therapies to effectively reduce lipoprotein(a). This article raises awareness of the importance of measurement of lipoprotein(a) for the assessment of cardiovascular disease risk and gives guidance to clinical laboratories regarding choice of appropriate assays.
Author(s): Cegla J, France M, Marcovina SM, Neely RDG
Publication type: Review
Publication status: Published
Journal: Annals of Clinical Biochemistry
Year: 2021
Volume: 58
Issue: 1
Pages: 16-21
Print publication date: 01/01/2021
Online publication date: 28/10/2020
Acceptance date: 01/10/2020
ISSN (print): 0004-5632
ISSN (electronic): 1758-1001
Publisher: SAGE Publications Ltd
URL: https://doi.org/10.1177/0004563220968473
DOI: 10.1177/0004563220968473
PubMed id: 33040574
